ClinicalTrials.gg
RecruitingNCT06272461Updated Nov 18, 2025

Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery

An interventional study of Lidocaine IV and Ketamine Injectable Solution in Colorectal (Colon or Rectal) Cancer and Inflammation, sponsored by University Tunis El Manar. Recruiting at 1 site in Tunisia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by University Tunis El Manar · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Oct 2023, registered Jan 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Patients undergoing open colorectal surgery were randomly divided into two groups: Intravenous Lidocaine (IV-Lido) vs Intravenous Ketamine (IV-Keta).

For the IV-Lido group, patients received a loading dose of Lidocaine than a continuous infusion over twenty-four hours.

For the IV-Keta goup, patients received a loading dose of Ketamine than a continuous injection of Ketamine over twenty-four hours.

Plasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively.

Read the detailed description

Patients undergoing open colorectal surgery with tumor resection were randomised prospectively into two groups: Intravenous Lidocaine (IV-Lido) vs Intravenous Ketamine (IV-Keta).

For the IV-Lido group (n=25), patients received a loading dose of 1.5 mg/kg of Lidocaine than a continuous infusion of 1.5 mg/kg/h over twenty-four hours.

For the IV-Keta goup(n=25), patients received a loading dose of 0.15mg/kg of Ketamine than a continuous injection of 0.15 mg/kg/h of Ketamine over twenty-four hours.

For both groups, plasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively. Plasma IL-6 concentrations at each point were compared between the groups.

02

Conditions studied

  • Colorectal (Colon or Rectal) Cancer
  • Inflammation
03

In context

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

This study's planned enrollment of 50 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

University Tunis El Manar is the lead sponsor of 74 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 or older.
  • ' (ASA) physical status of I-III.
  • Elective open colorectal surgery.

NON INCLUSION CRITERIA:

  • Patients with to lidocaine or ketamine.
  • therapy within the last 6 months.
  • History of therapy.
  • History of surgery in the last 3 months.
  • Personal medical history of inflammatory bowel disease.
  • Personal medical history of cardiac arrythmias or conduction disorders.
  • Alcohol or drug abuse.
  • Chronic use of opioids or benzodiazepines.

Exclusion criteria

EXCLUSION CRITERIA:

  • Severe intraoperative complications.
  • Duration of surgery longer than 5 hours.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    IV-Lido

    Intravenous Lidocaine dose loading than continuous infusion

    Drug: Lidocaine IV

  • Active comparator
    IV-Keta

    Intravenous Ketamine dose loading than continuous infusion

    Drug: Ketamine Injectable Solution

Interventions

  • Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer

  • Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer

06

What researchers measure

Primary outcomes

  1. The variation of Interleukin-6 levels

    The difference of Interleukine-6 (IL-6) plasma concentration between baseline values and 24 hours after surgery.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Pain assessed by Numerical Rating Scale (NRS)

    Postoperative pain was assessed by the Numerical Rating Scale (NRS)

    Time frame: Postoperatively, at Hour 2, Hour 12 and Hour 24. the patient asked to circle the number between 0 and 10:"0" usually represents 'no pain at all' whereas "10" represents 'the worst pain ever possible'.

  2. Post-operative nausea and vomiting

    Incidence of post-operative nausea and vomiting during the first 24 hours.

    Time frame: During the first 24 hours postoperatively

  3. Bowel function.

    Time to return of bowel function.

    Time frame: During the first 24 hours postoperatively

  4. Hospital length of stay.

    Hospital length of stay ( in days)

    Time frame: From date of randomization until the date of to discharge from the hospital assessed up to 15 days

  5. Post-operative complications.

    Incidence of intrahospital post-operative complications.

    Time frame: From date of randomization until the date of to discharge from the hospital assessed up to 15 days

07

Study locations

1 of 1 sites recruiting
  • Tunisia
    Nabeul, 8000, Tunisia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Feb 2026, 28 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 28 months is close to that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Feb 22, 2024
StartActual
Oct 1, 2023
Primary completionEst.
Feb 10, 2026
CompletionEst.
Mar 30, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06272461
Lead sponsor
University Tunis El Manar
Responsible party
HibetAllah Ktata (Associate Professor, University Tunis El Manar) — Principal investigator
First posted
Feb 22, 2024
Start date
Oct 1, 2023
Primary completion
Feb 10, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

BEN ALI MECHAAL, Professor
Contact
mechaal_benali@yahoo.fr
72100533 ext. 00216
KTATA HIBA, Dr
Contact
Hibetallah.ktata@fmt.utm.tn
72100500 ext. 00216
BEN ALI MECHAAL, Professor
principal investigator · university manar Tunis, Tunisia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion